RGS10 and ovarian cancer: Nonetheless, the decrease in cytotoxicity of chemotherapeutics following RGS10 or RGS17 knock-down clearly indicate that the suppression of these proteins promotes cell survival and suggest a decrease in the expression levels of RGS10 or RGS17 are sufficient to lower ovarian cancer cell sensitivity to chemotherapeutic cytotoxicity.